Suppr超能文献

新型冠状病毒肺炎相关过度炎症综合征的临床标准:一项队列研究

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.

作者信息

Webb Brandon J, Peltan Ithan D, Jensen Paul, Hoda Daanish, Hunter Bradley, Silver Aaron, Starr Nathan, Buckel Whitney, Grisel Nancy, Hummel Erika, Snow Gregory, Morris Dave, Stenehjem Eddie, Srivastava Rajendu, Brown Samuel M

机构信息

Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Intermountain Medical Center, Salt Lake City, UT, USA.

Division of Infectious Diseases and Geographic Medicine, Stanford Medicine, Palo Alto, CA, USA.

出版信息

Lancet Rheumatol. 2020 Dec;2(12):e754-e763. doi: 10.1016/S2665-9913(20)30343-X. Epub 2020 Sep 29.

Abstract

BACKGROUND

A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop and validate diagnostic criteria for cHIS in a cohort of inpatients with COVID-19.

METHODS

We searched for clinical research articles published between Jan 1, 1990, and Aug 20, 2020, on features and diagnostic criteria for secondary haemophagocytic lymphohistiocytosis, macrophage activation syndrome, macrophage activation-like syndrome of sepsis, cytokine release syndrome, and COVID-19. We compared published clinical data for COVID-19 with clinical features of other hyperinflammatory or cytokine storm syndromes. Based on a framework of conserved clinical characteristics, we developed a six-criterion additive scale for cHIS: fever, macrophage activation (hyperferritinaemia), haematological dysfunction (neutrophil to lymphocyte ratio), hepatic injury (lactate dehydrogenase or asparate aminotransferase), coagulopathy (D-dimer), and cytokinaemia (C-reactive protein, interleukin-6, or triglycerides). We then validated the association of the cHIS scale with in-hospital mortality and need for mechanical ventilation in consecutive patients in the Intermountain Prospective Observational COVID-19 (IPOC) registry who were admitted to hospital with PCR-confirmed COVID-19. We used a multistate model to estimate the temporal implications of cHIS.

FINDINGS

We included 299 patients admitted to hospital with COVID-19 between March 13 and May 5, 2020, in analyses. Unadjusted discrimination of the maximum daily cHIS score was 0·81 (95% CI 0·74-0·88) for in-hospital mortality and 0·92 (0·88-0·96) for mechanical ventilation; these results remained significant in multivariable analysis (odds ratio 1·6 [95% CI 1·2-2·1], p=0·0020, for mortality and 4·3 [3·0-6·0], p<0·0001, for mechanical ventilation). 161 (54%) of 299 patients met two or more cHIS criteria during their hospital admission; these patients had higher risk of mortality than patients with a score of less than 2 (24 [15%] of 138 one [1%] of 161) and for mechanical ventilation (73 [45%] three [2%]). In the multistate model, using daily cHIS score as a time-dependent variable, the cHIS hazard ratio for worsening from low to moderate oxygen requirement was 1·4 (95% CI 1·2-1·6), from moderate oxygen to high-flow oxygen 2·2 (1·1-4·4), and to mechanical ventilation 4·0 (1·9-8·2).

INTERPRETATION

We proposed and validated criteria for hyperinflammation in COVID-19. This hyperinflammatory state, cHIS, is commonly associated with progression to mechanical ventilation and death. External validation is needed. The cHIS scale might be helpful in defining target populations for trials and immunomodulatory therapies.

FUNDING

Intermountain Research and Medical Foundation.

摘要

背景

一部分新冠病毒病(COVID-19)患者会出现一种高炎症综合征,该综合征与其他高炎症性疾病有相似之处。然而,尚未确立专门用于定义COVID-19相关高炎症综合征(cHIS)的临床标准。我们旨在制定并验证COVID-19住院患者队列中cHIS的诊断标准。

方法

我们检索了1990年1月1日至2020年8月20日期间发表的关于继发性噬血细胞性淋巴组织细胞增生症、巨噬细胞活化综合征、脓毒症巨噬细胞活化样综合征、细胞因子释放综合征和COVID-19的特征及诊断标准的临床研究文章。我们将已发表的COVID-19临床数据与其他高炎症或细胞因子风暴综合征的临床特征进行了比较。基于保守临床特征框架,我们制定了cHIS的六标准相加量表:发热、巨噬细胞活化(高铁蛋白血症)、血液学功能障碍(中性粒细胞与淋巴细胞比值)、肝损伤(乳酸脱氢酶或天冬氨酸转氨酶)、凝血病(D-二聚体)和细胞因子血症(C反应蛋白、白细胞介素-6或甘油三酯)。然后,我们在山间前瞻性观察性COVID-19(IPOC)登记处连续入院且经聚合酶链反应确诊为COVID-19的患者中,验证了cHIS量表与住院死亡率和机械通气需求的相关性。我们使用多状态模型来估计cHIS的时间影响。

结果

我们纳入了2020年3月13日至5月5日期间因COVID-19住院的299例患者进行分析。cHIS每日最高评分对住院死亡率的未调整鉴别度为0.81(95%CI 0.74-0.88),对机械通气的未调整鉴别度为0.92(0.88-0.96);这些结果在多变量分析中仍然显著(死亡率的比值比为1.6[95%CI 1.2-2.1],p=0.0020,机械通气的比值比为4.3[3.0-6.0],p<0.0001)。299例患者中有161例(54%)在住院期间符合两条或更多cHIS标准;这些患者的死亡风险高于评分低于2分的患者(138例中的24例[15%]对161例中的1例[1%])以及机械通气风险(73例[45%]对3例[2%])。在多状态模型中,将每日cHIS评分作为时间依赖性变量,cHIS从低氧需求恶化到中等氧需求的风险比为1.4(95%CI 1.2-1.6),从中等氧需求恶化到高流量氧需求为2.2(从1.1-4.4),到机械通气为4.0(1.9-8.2)。

解读

我们提出并验证了COVID-19中高炎症的标准。这种高炎症状态,即cHIS,通常与进展到机械通气和死亡相关。需要进行外部验证。cHIS量表可能有助于确定试验和免疫调节治疗的目标人群。

资金来源

山间研究与医学基金会。

相似文献

1
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.
Lancet Rheumatol. 2020 Dec;2(12):e754-e763. doi: 10.1016/S2665-9913(20)30343-X. Epub 2020 Sep 29.
3
Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients.
J Intensive Care Med. 2023 Jan;38(1):70-77. doi: 10.1177/08850666221131265. Epub 2022 Oct 10.
6
Drugs for paediatric hyperinflammatory syndromes.
Drugs Context. 2022 May 27;11. doi: 10.7573/dic.2022-2-1. eCollection 2022.
7
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
Lancet Rheumatol. 2021 Apr;3(4):e253-e261. doi: 10.1016/S2665-9913(21)00012-6. Epub 2021 Feb 3.

引用本文的文献

2
Potential Predictors of the Outcome of Tocilizumab Treatment in Patients with COVID-19-Associated Hyperinflammation.
Infect Dis Clin Microbiol. 2025 Jun 26;7(2):185-194. doi: 10.36519/idcm.2025.475. eCollection 2025 Jun.
5
Long-term outcomes of patients with pre-existing coronary artery disease after SARS-CoV-2 infection.
EBioMedicine. 2025 Jun;116:105778. doi: 10.1016/j.ebiom.2025.105778. Epub 2025 May 28.
6
Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer's disease.
Brain Behav Immun Health. 2025 Apr 30;46:101007. doi: 10.1016/j.bbih.2025.101007. eCollection 2025 Jul.
7
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.
JAMA Netw Open. 2025 Apr 1;8(4):e253455. doi: 10.1001/jamanetworkopen.2025.3455.
8
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.
PLoS One. 2025 Apr 2;20(4):e0320251. doi: 10.1371/journal.pone.0320251. eCollection 2025.
10
Macrophage activation syndrome in Kawasaki disease: a literature review of Korean studies.
J Rheum Dis. 2025 Apr 1;32(2):105-112. doi: 10.4078/jrd.2024.0118. Epub 2025 Feb 3.

本文引用的文献

1
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
4
Presence of Genetic Variants Among Young Men With Severe COVID-19.
JAMA. 2020 Aug 18;324(7):663-673. doi: 10.1001/jama.2020.13719.
5
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.
Lancet Haematol. 2020 Aug;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7. Epub 2020 Jun 30.
6
Is a "Cytokine Storm" Relevant to COVID-19?
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154. doi: 10.1001/jamainternmed.2020.3313.
9
Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19.
J Neurol Sci. 2020 Jul 15;414:116943. doi: 10.1016/j.jns.2020.116943. Epub 2020 May 23.
10
COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion.
J Neurol Sci. 2020 Aug 15;415:116941. doi: 10.1016/j.jns.2020.116941. Epub 2020 May 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验